Stewart & Patten Co. LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 199,941 shares of the company’s stock after selling 2,191 shares during the quarter. Johnson & Johnson accounts for about 5.3% of Stewart & Patten Co. LLC’s investment portfolio, making the stock its biggest holding. Stewart & Patten Co. LLC’s holdings in Johnson & Johnson were worth $25,802,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the company. Stuart Chaussee & Associates Inc. increased its position in Johnson & Johnson by 20.7% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares in the last quarter. Deane Retirement Strategies Inc. increased its position in Johnson & Johnson by 0.7% in the fourth quarter. Deane Retirement Strategies Inc. now owns 12,458 shares of the company’s stock worth $1,608,000 after buying an additional 82 shares in the last quarter. Iron Financial LLC increased its position in Johnson & Johnson by 1.8% in the fourth quarter. Iron Financial LLC now owns 4,811 shares of the company’s stock worth $621,000 after buying an additional 87 shares in the last quarter. Aries Wealth Management increased its position in Johnson & Johnson by 0.7% in the fourth quarter. Aries Wealth Management now owns 13,897 shares of the company’s stock worth $1,793,000 after buying an additional 102 shares in the last quarter. Finally, Northside Capital Management LLC increased its position in Johnson & Johnson by 1.0% in the fourth quarter. Northside Capital Management LLC now owns 10,903 shares of the company’s stock worth $1,407,000 after buying an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 67.32% of the company’s stock.
A number of analysts have commented on the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “sell” rating in a research report on Tuesday, December 18th. Citigroup upped their price target on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Morgan Stanley set a $140.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Thursday, December 20th. Barclays restated an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Finally, Wells Fargo & Co restated an “outperform” rating and issued a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $143.58.
NYSE JNJ opened at $138.02 on Wednesday. The stock has a market capitalization of $370.29 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 2.21 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. The firm had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.06 earnings per share. Equities research analysts predict that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) is Stewart & Patten Co. LLC’s Largest Position” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2019/04/17/johnson-johnson-jnj-is-stewart-patten-co-llcs-largest-position.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What type of investment options does a Roth IRA provide?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.